Stockscreener 앱 받기
45.14
5.35%
-2.55
시간 외 거래:
45.14
Crinetics Pharmaceuticals Inc 주식(CRNX)의 최신 뉴스
Crinetics Pharmaceuticals CEO Scott Struthers to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 7.9%Here's Why - MarketBeat
Crinetics Pharmaceuticals (CRNX) Stock Drops After CMO Departure Filing: Latest News, Analyst Forecasts, and What’s Next (Dec. 18, 2025) - ts2.tech
Crinetics Pharmaceuticals stock falls after CMO departure announcement - Investing.com
Crinetics Pharmaceuticals Shares Fall After Chief Medical, Development Officer Steps Down - marketscreener.com
Why Crinetics Pharmaceuticals Shares Are Sinking Today - TipRanks
What risks investors should watch in Crinetics Pharmaceuticals Inc. stockStop Loss & Daily Entry Point Alerts - Улправда
How Crinetics Pharmaceuticals Inc. stock trades during market volatilityEarnings Miss & Technical Confirmation Trade Alerts - Улправда
What is HC Wainwright's Estimate for CRNX FY2025 Earnings? - MarketBeat
Sanders Morris Harris LLC Takes Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Will Crinetics’ (CRNX) First SST2 NDC Trial and Atumelnant Milestone Reframe Its Pipeline Narrative? - simplywall.st
Crinetics Pharmaceuticals Inc (CRNX) - MSN
CRNX stock touches 52-week low at $35.47 amid market shifts - MSN
Does Crinetics Pharmaceuticals Still Offer Value After Its Recent Share Price Rebound? - Yahoo Finance
Trading the Move, Not the Narrative: (CRNX) Edition - news.stocktradersdaily.com
Crinetics Pharmaceuticals (CRNX) Valuation Check After First-Patient Dosing in New SST2 Tumor Trial - Sahm
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) - Koreabizwire
Crinetics Pharmaceuticals Doses First Patient in Phase 3 Trial of Atumelnant for Classic Congenital Adrenal Hyperplasia - Quiver Quantitative
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital ... - Enidnews.com
Crinetics (NASDAQ: CRNX) doses first patient in Phase 3 CALM-CAH trial of atumelnant - Stock Titan
Crinetics Pharmaceuticals (CRNX) poised for transformational growth in 2026: Piper Sandler - MSN
Crinetics Pharmaceuticals (CRNX) Poised for Transformational Growth in 2026: Piper Sandler - Yahoo Finance
Crinetics Pharmaceuticals, Inc. (CRNX) Poised for Transformational Growth in 2026: Piper Sandler - Insider Monkey
15 Best Biotech Stocks to Buy According to Wall Street Analysts - Insider Monkey
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Crinetics (Nasdaq: CRNX) issues 39,575 options, 26,525 RSUs to 9 new hires - Stock Titan
JPMorgan Chase & Co. Has $9.55 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Did First-in-Human BRAVESST2 Trial of CRN09682 Just Shift Crinetics Pharmaceuticals' (CRNX) Investment Narrative? - Sahm
Crinetics Pharmaceuticals, Inc. $CRNX Stock Holdings Increased by Walleye Capital LLC - MarketBeat
Schroder Investment Management Group Purchases 63,517 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
How Crinetics Pharmaceuticals Inc. (6Z4) stock moves in volatile trading sessionsMarket Sentiment Summary & Daily Profit Focused Screening - Newser
Can Crinetics Pharmaceuticals Inc. (6Z4) stock surprise markets with earningsEntry Point & Advanced Technical Signal Analysis - Newser
CRNX SEC FilingsCrinetics Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Why Crinetics Pharmaceuticals Inc. stock could outperform in 2025July 2025 Opening Moves & Entry and Exit Point Strategies - Newser
Is Crinetics Pharmaceuticals Inc. stock gaining market share2025 Performance Recap & Reliable Intraday Trade Plans - Newser
Decheng Capital LLC Cuts Stake in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
How strong dollar benefits Crinetics Pharmaceuticals Inc. (6Z4) stockStock Surge & Weekly High Return Stock Opportunities - Newser
Why Crinetics Pharmaceuticals Inc. (6Z4) stock stays resilient2025 Year in Review & Real-Time Volume Analysis Alerts - Newser
Crinetics doses first patient in phase 1/2 trial of novel cancer drug By Investing.com - Investing.com South Africa
Crinetics Pharmaceuticals Executive Sells 5,000 Shares - TradingView
Carcinoid Syndrome Market to Expand Significantly by 2034, - openPR.com
Crinetics Pharmaceuticals (CRNX): Reassessing Valuation After a 3-Month Rebound and DCF Upside Signal - Yahoo Finance
Assessing Crinetics Pharmaceuticals Valuation After Stock Volatility and Pipeline Progress in 2025 - Sahm
Crinetics Pharmaceuticals Says First Patient Dosed in Phase 1/2 Neuroendocrine Tumors Study - MarketScreener
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors - Koreabizwire
Crinetics announces first patient dosed in phase 1/2 trial evaluating CRN09682 - MarketScreener
Crinetics Pharmaceuticals doses first patient in novel tumor treatment trial - Traders Union
Crinetics doses first patient in phase 1/2 trial of novel cancer drug - Investing.com Australia
Crinetics (CRNX) Advances CRN09682 in Clinical Trials for Neuroe - GuruFocus
Crinetics (Nasdaq: CRNX) starts Phase 1/2 BRAVESST2 trial of CRN09682 NDC therapy - Stock Titan
Fisher Asset Management LLC Cuts Holdings in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Is Crinetics Pharmaceuticals Inc. (6Z4) stock prepared for digital transitionQuarterly Risk Review & Free Weekly Watchlist of Top Performers - Newser
XTX Topco Ltd Acquires Shares of 34,013 Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Prudential Financial Inc. Has $4.69 Million Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharmaceuticals, Inc. $CRNX Shares Purchased by American Century Companies Inc. - MarketBeat
0.31%
0.33%
자본화:
|
볼륨(24시간):